Gene Delivery and Gene Editing

Dear Colleagues,

Advances in gene delivery and editing technologies are bringing us closer to realizing fundamental and curative treatments for diseases caused by genetic mutations. Genetic recombinants can now be easily produced on a laboratory scale, serving as model cells or animals for various diseases, such as cancer, immunological disorders, and neurological conditions. These sources and technologies are instrumental in establishing model systems for signaling pathways, investigating fundamental causes, and developing treatments.

While gene delivery and editing technologies have become commonplace due to the prevalence of highly advanced methods, it is essential to recognize that ongoing development is imperative. The ultimate role of genetic engineers is to acquire a flawless technology that can, in a specific and efficient manner, revert mutated or defective genes to their healthy wild-type form without any side effects.

In this Special Issue, we aim to compile reviews addressing the current status, challenges, and issues related to gene editing, gene delivery technologies, and peripheral technologies in drug development, diagnostics, and medicine. We also expect comprehensive articles that present new insights from diverse perspectives. We are particularly interested in exploring the potential of new functional modules for CRISPR-Cas, proteins beyond typical Cas proteins, advancements in TALEN, the discovery and characterization of unknown type I or II transposons and viruses, and the medical applications stemming from these discoveries.

Dr. Kosuke Ishikawa
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• gene delivery
• gene editing
• novel module
• transposon
• genetic engineering